The researchers attached heparin-binding peptides from antithrombin III to a synthetic material called polyethylene glycol.
研究人员将抗凝血酶III上的肝素结合肽段黏附在称为聚乙二醇的人工合成材料上。
AIM To investigate the association between antithrombin activity at admission to the ICU(ICU-antithrombin activity) and various outcome variables.
目的观察患者回到ICU后的抗凝血酶活性以及术后各种不良结果的联系。
Conclusions venous thrombosis can result in decreased antithrombin activity, and increased lupus_like anticoagulants is one of the factors that lead to venous thrombosis.
结论静脉血栓形成可导致抗凝血酶活性下降，狼疮样抗凝物质增多是导致静脉血栓形成的因素之一。
Heterozygous type I (quantitative) and most type II (qualitative) antithrombin deficiencies highly increase the risk of venous thromboembolism (VTE), while homozygous mutations are lethal.
杂合子i型(定量)和大多数II型(定性)抗凝血酶缺乏症使静脉血栓栓塞(VTE)的风险显着增加，而纯合型突变会导致死亡。
Researchers have used the interaction between a polysaccharide called heparin and a peptide fragment of a protein called antithrombin III, which is contained in the bloodstream to control clotting.
研究者利用了肝素（一种多糖）和血液中的抗凝血酶III（一种多肽片断）之间的相互作用来控制凝固时间。
Researchers have used the interaction between a polysaccharide called heparin and a peptide fragment of a protein called antithrombin III, which is contained in the bloodstream to control clotting.
研究者利用了肝素（一种多糖）和血液中的抗凝血酶III（一种多肽片断）之间的相互作用来控制凝固时间。
应用推荐